T1	intervention 12 43	tamoxifen following anastrozole
T2	control 71 102	anastrozole following tamoxifen
T3	total-participants 360 364	1021
T4	eligibility 381 428	patients with hormone receptor-positive tumours
T5	intervention-participants 797 800	511
T6	total-participants 919 922	119
T7	control-participants 1100 1103	510
T8	outcome 849 879	received second-line tamoxifen
T9	iv-bin-abs 837 840	137
T10	iv-bin-percent 842 847	26.8%
T11	iv-bin-abs 933 935	58
T12	iv-bin-percent 937 942	48.7%
T13	outcome 944 967	gained clinical benefit
T14	iv-bin-abs 1048 1050	12
T15	iv-bin-percent 1052 1057	10.1%
T16	outcome 1066 1084	objective response
T17	cv-bin-abs 1138 1141	134
T18	cv-bin-percent 1143 1148	26.3%
T19	outcome 1150 1182	received second-line anastrozole
T20	cv-bin-abs 1232 1234	54
T21	cv-bin-percent 1236 1241	56.8%
T22	outcome 1243 1252	gained CB
T23	cv-bin-abs 1257 1258	7
T24	cv-bin-percent 1287 1291	7.4%
T25	outcome 1300 1302	OR
T26	outcome 496 521	time to progression (TTP)
T27	iv-cont-median 559 563	10.7
T28	cv-cont-median 571 581	6.4 months
